Navigation Links
Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
Date:3/17/2008

Clinical study to commence late this year

MELBOURNE, Australia, March 17 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease.

Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET) that affect over 150,000 patients in the USA and more than twice that worldwide. Over 95% of PV cases and over 50% of ET and primary and secondary myelofibrosis cases are believed to be caused by a mutation in the JAK2 kinase enzyme. This renders the kinase permanently active and leads to the overproduction of particular blood cells.

No specific treatments exist for these diseases and untreated progressive disease can lead to leukemia or myelofibrosis. CYT387 possesses an excellent selectivity profile against a large panel of kinases and other pharmacological targets. It also has excellent pharmacokinetics including oral bioavailability and in preclinical models has a promising safety profile.

CYT387 has also recently shown efficacy in a well-validated in-vivo model of myeloproliferative disorders in studies in the laboratory of physician- scientist Michael Deininger MD PhD at Oregon Health & Science University Cancer Institute, USA. Results showed a profound effects on abnormal blood counts and clinical symptoms of MPDs in mice that were dosed orally.

Dr Deininger said, "We are highly encouraged by Cytopia's compound in this model of myeloproliferative disease which clearly indicates significant improvement of symptoms and disease remission. The favorable data from this animal model augers well for activity of the compound in the clinic."

The compound will now be progres
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
2. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
5. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
6. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
11. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... 22, 2014 NxStage Medical, Inc. (NASDAQ: ... dialysis products, announced today that the U.S. Food ... One™ to perform hemodialysis overnight while the patient ... hemodialysis. NxStage,s® System One is the first and ... this indication. Home nocturnal hemodialysis ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... WASHINGTON, March 7, 2011 RainDance Technologies, Inc. ... focused on the development and commercialization of a ... genetic screening panel for use on next-generation sequencing ... with the Society of Toxicology,s 50th Annual Meeting ...
... March 7, 2011 Dyadic International, Inc. (OTC Pink: ... will release financial results for the year ended December ... open to be followed by a conference call at ... The conference call may be accessed by dialing ...
Cached Medicine Technology:RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis 2RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis 3RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis 4
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2
... Group, Inc.,(NYSE Alternext US: QGP) ( www.QuantumMD.com ) announced ... debut at the 2009 Pri-Med,South Conference and Expo alongside ... Quantum believes PWeR is the next generation in healthcare ... Obama is calling for within,the industry. Pete Martinez, ...
... . , This minimally invasive procedure, pioneering ... surgeons at the University Hospital of Navarra, which brings ... , The results obtained in patients were recently published ... Annals of Surgery . It is the highest ...
... research plays a significant role in African-Americans, lack ... study by researchers at Children,s Hospital of Pittsburgh ... School of Public Health. , African-Americans are ... published in the February issue of Archives ...
... Iowa, Feb. 3 Bio-Research Products,announced today that it ... enzyme Glutathione Reductase (GR). Dr. Bryce Cunningham, President and,Chief ... first,commercial version of the enzyme as a readily soluble ... Glutathione Reductase is part of test kits ...
... New hidden-camera footage from Tucson, AZ, implicates a ... scandal. In the video, UCLA student Lila ... Planned Parenthood clinic where Rose tells the nurse that ... 27-year-old boyfriend. The nurse disregards the age difference and ...
... The Center for Association Resources, an,association management and ... is pleased to announce the launch of an,innovative e-learning ... in the,healthcare industry. The implementation of the service will ... as deliver educational segments via,CCTV. , ...
Cached Medicine News:Health News:PWeR(TM) Introduced at Regional Healthcare Conference 2Health News:PWeR(TM) Introduced at Regional Healthcare Conference 3Health News:PWeR(TM) Introduced at Regional Healthcare Conference 4Health News:Surgical technique in Spain enables extirpation of benign tumors of the pancreas 2Health News:Children's Hospital study finds African-Americans more distrusting of research than whites 2Health News:Children's Hospital study finds African-Americans more distrusting of research than whites 3Health News:New Undercover Video Shows Tucson Planned Parenthood Hiding Rape of 15-Year-Old Girl 2Health News:Center for Association Resources Launches E-Learning Service 2
... The table top design takes into account ... creates a flexible working environment for the ... alphamaxx can be matched exactly to your ... slide capability creates superior access for image ...
... is the Market leader in soft tissue ... DePuy Mitek has developed the latest evolution ... shoulder repair. ORTHOCORD Suture is as strong ... market. Most importantly, ORTHOCORD Suture handles like ...
... Now you can ... tactile sensitivity of the ... Free surgical gloves on ... Free gloves provide the ...
... Siegel MAST Intraoperative Leg Positioner frees the OR ... need for 2nd assistants to hold the leg, ... the procedure instead of leg positioning. The Siegel ... the leg in any position required for knee ...
Medicine Products: